Elicio Therapeutics is an immuno-oncology company, engineering therapies for cancer-killing immune responses. The Company is engineering potent cancer vaccines and immunotherapies for an array of aggressive solid and hematologic cancers. Elicio operates Amphiphile, a platform which enables precise targeting and delivery of immunogens directly to the lymphatic system, substantially enhancing the body’s own system of immune defenses, with the aim to achieve durable cures.
|Employees (est.) (Mar 2020)||15||(+8%)|
Elicio Therapeutics total Funding
Elicio Therapeutics latest funding size
Time since last funding
|6 months ago|
Elicio Therapeutics investors
|Clal Biotechnology Industries, EFung Capital, Livzon Pharmaceutical Group|
When was Elicio Therapeutics founded?
Elicio Therapeutics was founded in 2018.
How many employees does Elicio Therapeutics have?
Elicio Therapeutics has 15 employees.
Who are Elicio Therapeutics competitors?
Competitors of Elicio Therapeutics include DNAtriX, Inhibitor Therapeutics and Actuate Therapeutics.
Where is Elicio Therapeutics headquarters?
Elicio Therapeutics headquarters is located at One Kendall Square Building 300 Suite 201, Cambridge.
Where are Elicio Therapeutics offices?
Elicio Therapeutics has an office in Cambridge.
How many offices does Elicio Therapeutics have?
Elicio Therapeutics has 1 office.
Receive alerts for 300+ data fields across thousands of companies